CJC-1295 is a long-acting GHRH analogue and ipamorelin is a selective ghrelin mimetic. Research on each compound and their studied effects on GH secretion profiles.
Written by the Peptide Labs Research Team
CJC-1295 is a modified GHRH analogue that activates the GHRH receptor, while ipamorelin is a pentapeptide that activates the ghrelin receptor (GHS-R1a). Researchers pair them because the receptors sit on separate pathways that converge on growth hormone release from pituitary somatotrophs.
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor target | GHRH-R | GHS-R1a (ghrelin receptor) |
| Molecular weight | 3647.1 Da | 711.85 Da |
| CAS number | 863288-34-0 | 170851-70-4 |
CJC-1295 is a tetrasubstituted GHRH(1-29) analogue. Four amino acid substitutions confer DPP-IV resistance, and a maleimidoproprionic acid side chain binds albumin covalently (the Drug Affinity Complex, or DAC). Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2).
The rationale is that GHRH receptor and GHS-R1a signalling act synergistically in somatotroph physiology. Ipamorelin is characterised as a selective secretagogue, making it a more specific tool than earlier secretagogues for GH axis studies. Our CJC-1295 and Ipamorelin 10mg Blend provides both compounds at research-grade purity, independently HPLC verified with full COA documentation.
| Property | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|
| Class | GHRH analogue | Ghrelin mimetic (GHRP) |
| Target | GHRH-R | GHS-R1a |
| Structure | Mod GRF(1-29) + maleimide albumin-binding linker | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Molecular weight | ~3647.2 Da | ~711.9 Da |
| Formula | C₁₆₅H₂₆₉N₄₇O₄₆ | C₃₈H₄₉N₉O₅ |
| CAS number | 863288-34-0 | 170851-70-4 |
| Half-life | Several days | Not established |
| Human evidence | Early / small human studies | No published human trials |
| Studied in |
|
|
| Notes | Produces sustained elevation rather than a pulse. | Selective: minimal cortisol/prolactin/ACTH effect in published pharmacology. |
| Availability | In catalogue$159.99 | In catalogue$74.99 |
Molecular data from the certificate of analysis for each batch. Half-life and evidence level reflect the published literature cited in our research articles. Research use only.
Educational use only. These compounds are sold strictly for in-vitro laboratory and research use. Not medical advice.
VRX-0075 is a preclinical quintuple agonist reported to reduce body weight more than retatrutide in rats. What the ADA 2026 abstract shows and does not.
ResearchBrenipatide (LY3537031) is Lilly's investigational GIP/GLP-1 agonist, in phase 3 for alcohol use disorder and depression. Registered trials and unknowns.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides